Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Goodwill (2021 - 2024)

Barinthus Biotherapeutics (BRNS) has disclosed Goodwill for 4 consecutive years, with $12.2 million as the latest value for Q3 2024.

  • For Q3 2024, Goodwill changed 0.0% year-over-year to $12.2 million; the TTM value through Sep 2024 reached $12.2 million, changed 0.0%, while the annual FY2023 figure was $12.2 million, 0.07% changed from the prior year.
  • Goodwill hit $12.2 million in Q3 2024 for Barinthus Biotherapeutics, roughly flat from $12.2 million in the prior quarter.
  • Across five years, Goodwill topped out at $12.6 million in Q4 2021 and bottomed at $12.2 million in Q4 2023.
  • Average Goodwill over 4 years is $12.3 million, with a median of $12.2 million recorded in 2022.
  • Year-over-year, Goodwill dropped 3.33% in 2022 and then changed 0.0% in 2024.
  • Barinthus Biotherapeutics' Goodwill stood at $12.6 million in 2021, then decreased by 3.33% to $12.2 million in 2022, then decreased by 0.07% to $12.2 million in 2023, then rose by 0.07% to $12.2 million in 2024.
  • According to Business Quant data, Goodwill over the past three periods came in at $12.2 million, $12.2 million, and $12.2 million for Q3 2024, Q2 2024, and Q1 2024 respectively.